Biotech Archives - Page 772 of 795

2 minute read

FDA
News

Arbutus Biopharma Provides Update On The Phase 2A Combination Trial With AB-729 And A Capsid Inhibitor

July 20, 4:13 PM

Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that

ABUS

1 minute read

Chardan Initiates Coverage On These ‘Intriguing Small-Cap Stories”

By Vandana Singh

July 20, 3:50 PM

Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ:DYN) with…

DYN

1 minute read

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

By Vandana Singh

July 20, 3:50 PM

Portage Biotech Inc (NASDAQ:PRTG) acquired the remaining 22% stake in its invariant natural killer T cell (iNKT agonist) platform and now…

PRTG

1 minute read

Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study

By Vandana Singh

July 20, 3:16 PM

Soligenix Inc (NASDAQ:SNGX) announced the results of its Phase 3 FLASH study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL)…

SNGX

1 minute read

Aytu BioPharma Commences Late-Stage Genetic Disorder Study

By Ragothaman Srinivasan

July 20, 11:55 AM

Aytu BioPharma (NASDAQ: AYTU) has initiated the global Phase 3 PREVEnt clinical trial of Enzastaurin (AR101) for the treatment of patients with COL3A1-positive Vascular Ehlers-Danlos Syndrome (VEDS).

AYTU

1 minute read

AIM ImmunoTech Posts Additional Patient Data From Pancreatic Cancer Study

By Vandana Singh

July 20, 11:31 AM

AIM ImmunoTech Inc (NYSE:AIM) reported follow-on data from its published single-center named patient program. For the study, patients with locally advanced…

AIM

1 minute read

Soleno Shares Surge On Regulatory Update For Its Prader-Willi Syndrome Hopeful

By Vandana Singh

July 20, 10:59 AM

Soleno Therapeutics Inc (NASDAQ:SLNO) provided an update following recent communications with the FDA regarding the development of once-daily DCCR (diazoxide choline)…

SLNO

1 minute read

Rhythm Shares Shoot Higher Following Pre-marketing Authorization From French Regulatory For Multisystem Disorder Candidate

By Ragothaman Srinivasan

July 20, 10:30 AM

The French National Agency for Medicines and Health Products Safety (ANSM) and Haute Autorité de santé (HAS) have granted pre-marketing authorization AP1 (early access authorization), for Rhythm Pharmaceuticals’ (NASDAQ: RYTM) lead candidate IMCIVREE (setmelanotide) in patients with genetically-conf

RYTM

1 minute read

AIM ImmunoTech Reports Additional Patient Data From Single-center Named Patient Program Evaluating Ampligen As Maintenance Therapy For Advanced Pancreatic Cancer Indicating Additional Progression-free And Overall Survival Over Previously Published Data

By Benzinga Newsdesk

July 20, 8:09 AM

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC) New patient data

AIM

2 minute read

Merck Provides Update On Phase 3 KEYNOTE-412 Trial In Unresected Locally Advanced Head And Neck Squamous Cell Carcinoma; Trial Did Not Meet Primary Endpoint Of Event-Free Survival

By Bill Haddad

July 20, 6:46 AM

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-412 trial evaluating KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, with concurrent

MRK